The majority of adverse events (AEs) were mild, with the most common AEs being gastrointestinal disorders
This means compounding pharmacies are no longer allowed to produce compounded versions of these medications under the shortage exemption
External resources Nutritional Priorities to Support GLP-1 Therapy for Obesity - Joint Advisory (PMC) Strategies for Minimizing Muscle Loss During Incretin-Mimetic Drug Use (PMC) Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass - Diabetes Care For researchers serious about optimizing their peptide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, and a community of thousands who have navigated these exact questions
People often feel full sooner during meals, hunger signals become less intense, and cravings become easier to manage
The drug was originally developed for keeping Type 2 diabetes under control, but it was later approved by the FDA for weight loss as well